Interestingly, disruption of MCT1 or MCT4 in renal cell carcinoma, pancreatic cancer, breast cancer and prostate cancer has been shown to exert significant antitumor effects both in vivo and in vitro with increased accumulation of intracellular lactate (98, 99). The gene discussed is SLC16A1; the disease is Familial prostate cancer.